- PEGs by Application
- PEGs by Structure
-
PEG Linkers
- >PROTAC Linker
- >Methoxy PEG (mPEG)
- >Amine(NH2) PEG
- >DSPE PEG
- >Thiol(SH) PEG
- >Maleimide(Mal) PEG
- >DBCO PEG
- >Azide(N3) PEG
- >Carboxylic Acid(COOH) PEG
- >Acrylate(AC) PEG
- >Cyanine (Cy) PEG
- >NHS ester PEG
- >Biotin PEG
- >Aldehyde (Ald/CHO)PEG
- >Other Lipid PEG
- >Fluorescent (FITC) PEG
- >Cholesterol PEG
- >Hydroxyl(OH) PEG
- >OPSS PEG
- >Acrylamide(ACA) PEG
- >Epoxide (EPO) PEG
- >Hydrazide (HZ) PEG
- >Boc/Fmoc PEG
- > Folic Acid(FA) PEG
- >Lipoic acid(LA) PEG
- >Halide (F,Cl,Br,I) PEG
- >Methacrylate (MA) PEG
- >Rhodamine B(RB) PEG
- >Silane PEG
- >PLGA PEG
- >PCL PEG
- >PLA PEG
- >PEG Sulfonic acid
- >PEG PFP ester
- >PEG TFP ester
- >Benzyl-PEG
- >Aminooxy PEG
- >Hydrocarbons PEG
- >Nitrophenyl Carbonate (NPC) PEG
- >DNP PEG
- >Other PEG
- PEG in mRNA Vaccines
- PEG Raw Material
- Large Scale PEGs
PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules composed of two ligands; an “anchor” that binds to an E3 ubiquitin ligase and a “warhead” that binds to a protein of interest, connected by a chemical linker.
Figure 1: Schematic of typical PROTAC structure and an example (ARV-110).
PROTAC linker plays a vital role in efficient ubiquitination of the target protein and its ultimate degradation. To date, several kinds of linkers have been reported and applied in PROTAC ternary complexes formation, such as PEG linker, Alkyl linker, alkyne linkers, and click chemistry linker, etc.
PEG linkers are the most common motifs incorporated into PROTAC linker structures. According to statistics, 54% of the reported PROTAC molecules used PEG as a linker.
▶ The introduction of PEG can increase the water solubility of PROTAC molecules and affect cell permeability, thus affecting oral absorption.
▶ Systematic changes in linker length can be easily achieved by using PEGs of different chain lengths, affecting the degradation efficiency of PROTAC molecules.
▶ The use of various bifunctionalized PEG linkers enables the simple and rapid assembly of molecules with different linker groups and accelerates the screening of efficient degradation structures.
Biopharma PEG is dedicated to the R&D of PROTAC Linker, providing high purity PEG linkers with various reactive groups to continuously assist your project development.
References:
[1] Sun X, Gao H, Yang Y, et al. PROTACs: great opportunities for academia and industry.Signal Transduct Target Ther. 2019;4:64.
[2]Troup RI, Fallan C, Baud MGJ. Current strategies for the design of PROTAC linkers: a critical review. Explor Target Antitumor Ther. 2020;1:273-312. https://doi.org/10.37349/etat.2020.00018
| Catalog No. | Name | Structure | M.W. | Purity | Buy |
| MD016016 | COOH-PEG5-COOH |
|
382.403 | ≥95% | |
| MD038038 | Tos-PEG4-Tos |
|
502.6 | ≥95% | |
| MD068002 | Boc-NH-PEG2-OH |
|
205.252 | ≥95% | |
| MD068002 | Boc-NH-PEG3-OH |
|
249.3 | ≥95% | |
| MD068002 | Boc-NH-PEG4-OH |
|
293.4 | ≥95% | |
| MD068005 | BOC-NH-PEG2-NH2 |
|
248.3 | ≥95% | |
| MD068005 | BOC-NH-PEG3-NH2 |
|
292.4 | ≥95% | |
| MD068005 | BOC-NH-PEG5-NH2 |
|
380.5 | ≥95% | |
| MD069016 | Fmoc-NH-PEG3-COOH |
|
443.5 | ≥95% | |
| MD121288 | Pomalidomide-PEG4-C-COOH |
|
507.493 | ≥95% | |
| MD006002 | N3-PEG7-OH |
|
351.4 | ≥95% | |
| MD068038 | Boc-NH-PEG3-Tos |
|
447.54 | ≥95% |